Table 1.
Characteristics of study subjects.
| Total subjects (M/F) | 32 (16/16) | |
|---|---|---|
| Median age in years (IQR) | 13.6 (10.5-16.3; range 7.4-21.3) | |
| Race, n (%) | White | 25 (78%) |
| Black | 5 (16%) | |
| Other | 2 (6%) | |
| Wilms Tumor Stage, n (%) | Stage 1 | 2 (6%) |
| Stage 2 | 6 (19%) | |
| Stage 3 | 10 (31%) | |
| Stage 4 | 12 (38%) | |
| Stage 5 | 2 (6%) | |
| Median years from completion of treatment (IQR)* | 8.7 (6.5-10.8; range 1.0-18.0) | |
| Radiotherapy to the kidney, n (%) | 23/32 (72%) | |
| Radiotherapy to any other organ, n (%) | 11/23 (48%) | |
| Lung | 7/11 (64%) | |
| Abdomen | 2/11 (18%) | |
| IVC | 1/11 (9%) | |
| Whole Body | 1/11 (9%) | |
| Received chemotherapy | 32/32 (100%) | |
| Type of chemotherapy, n (%) | Vincristine | 32 (100%) |
| Doxorubicin | 24 (75%) | |
| Actinomycin-d | 32 (100%) | |
| Cyclophosphamide | 5 (16%) | |
| Etoposide | 5 (16%) | |
| Carboplatin | 4 (13%) | |
| Type of surgery, n (%) | Radical Nephrectomy | 29 (91%) |
| Bilateral Partial Nephrectomy | 2 (6%) | |
| Radical Plus Partial Nephrectomy | 1 (3%) | |
| eGFR median (IQR) | 95.6 (84.6-114.0) ml/min/1.73m2 | |
| GFR <90 ml/min/1.73m2 | 11/32 (34%) | |
GFR = glomerular filtration rate; IQR = interquartile range; IVC = inferior vena cava
*
median years from completion of treatment available only in 29 patients who completed ABPM